Skip to main content
OpenTrials
Completed

NCT Number: NCT03472859

Treatment of Dilated Blood Vessels on the Cheeks With a New Yellow Laser and a Traditional Green Laser

The goal is to compare a novel yellow laser, based on semiconductor technology, with traditional green laser, in the treatment of cheek telangiectasias. The trial design is randomized split-face double-blinded study with 20-30 volunteers. The improvement will be assessed using a 7-point Telangiectasia Grading Scale.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Telangiectasia Cardiovascular Diseases Rosacea Skin Diseases Skin and Connective Tissue Diseases Telangiectasis Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Epilaser Oy

Lempäälä, Pirkanmaa, 33880, Finland

About this study

Trial design: The study is a comparative randomized split-face double-blinded study without a control group. It enables a comparison between two lasers; namely the KTP laser and the investigational PHOTOLASE laser. The split-face design eliminates the individual biases and the randomization eliminates the possible small variations in the symmetry of the telangiectasias on the face. The double-blinded assessment eliminates the physicians' and the subjects' subjective and objective bias.

Methods: The subjects will be treated with a 532-nm green KTP laser and a 585-nm yellow PHOTOLASE laser; different laser on each side of a face. A total of one or two treatments will be given based on the response of the first treatment. The improvement of subjects' telangiectasia will be graded after the final treatment according to a 7-point Telangiectasia Grading Scale (TGS) by a blinded physician using images taken with Visia imaging system. The usability, reliability and treatment characteristics of PHOTOLASE laser will be qualitatively assessed by the treating physicians (not blinded).

Objectives: The primary objective is to assess how the PHOTOLASE laser compares to the KTP laser in the treatment of facial telangiectasia in terms of the treatment outcomes. The secondary objective is to assess the usability, reliability and treatment characteristics of the PHOTOLASE laser from the perspective of the user.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The subjects are required to be Finnish speaking adults with symmetrical facial telangiectasia, volunteering to participate in the clinical trial.
  • The subjects have to have a Fitzpatrick skin phototype I-IV.

Exclusion criteria

  • pregnancy
  • lactation
  • hemophilic condition
  • Fitzpatrick skin phototype V-VI
  • drug or alcohol abuse
  • subjects who are under guardianship
  • subjects with significant tanning less than 6 weeks prior to the treatment day.
  • unbalanced basic diseases, such as diabetes, heart disease, cancer etc.

Treatment and study plan

PHOTOLASE

Device

This is the investigational yellow laser (PHOTOLASE)

Other names: yellow laser

KTP

Device

This is the traditional green laser (KTP)

Other names: green laser

Primary outcomes

  1. TGS change

    Time frame: Before treatment and 1-2 months after the intervention.

    Telangiectasia grading scale will be used to assess improvement of telangiectasia and erythema. The range of TGS is -1 to 5, where -1 means worsening of the condition, 0 means no change, 1 means 0-25% improvement, 2 means 25-50% improvement, 3 means 50-75% improvement, 4 means 75-100% improvement and 5 means total clearance.

Secondary outcomes

  1. VAS pain measurement

    Time frame: Immediately after intervention.

    Visual Analogue Scale will be used to measure the amount of pain after the intervention. The range is 0.0 - 10.0, where 0 means no pain and 10 means worst imaginable pain. The results will be reported as a mean value and range for yellow laser and green laser separately.

  2. Amount of treatment-related adverse effects using a 4-point scale.

    Time frame: Immediately after treatment and 2-3 days after treatment.

    The amount of erythema, crusting, edema, purpura and blisters will be assessed separately on both sides of the face. The measurement range is 0-3, where 0 means no symptoms, 1 means mild symptoms, 2 means moderate symptoms and 3 means severe symptoms. The results will be reported as a mean value for yellow laser and green laser separately.

Sponsors and collaborators

Lead sponsor

Tampere University Hospital

Other

Collaborators

  • Tampere University of Technology

Registry information

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Mar 21, 2018
Registry last updated
Sep 13, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.